Pfizer drug extends survival for some bladder cancer patients

Taking stock of the drug industry, from the lab to the medicine chest

August 12, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Spencer Platt/Getty Images STAT+ | Pfizer drug extends survival for some bladder cancer patients Padcev, an antibody-drug conjugate that the drug giant acquired through its purchase of Seagen, was combined with Keytruda in clinical trial. By Matthew Herper STAT+ | Insmed's lung disease drug approved in the U.S. Insmed will market the daily pill, brensocatib, under the brand name Brinsupri and expects to see billions in sales. By Elaine Chen Opinion: Community pharmacies are in crisis. Three things need to change Policymakers need to act now to recognize pharmacists as health care providers, reform the broken reimbursement system, and protect community pharmacies. By Rick Gates Suzanne Kreiter/Globe staff STAT+ | Boston's lab building boom has gone bust. What can be done with the empty space? The amount of lab space in the region has doubled in the past five years, and now vacancy rates are at record highs. But re-using it is hard. By Catherine Carlock — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser